Search results for "Endocrine reproductive disorders"

showing 1 items of 1 documents

Metformin induces lipid changes on sphingolipid species and oxidized lipids in polycystic ovary syndrome women.

2019

Metformin is one of the treatments used for pcoS pathology decreasing body weight, plasma androgen, FSH and glucose levels. Unfortunately, there is little known about metformin’s effects on lipid metabolism, a crucial process in pcoS pathology. We have employed a lipidomic approach to explore alterations in the plasma lipid profile of patients with PCOS following metformin treatment. The aim is to offer new insights about the effect of metformin in PCOS patients. Plasma samples were obtained from 27 subjects prior to and following 12 weeks of metformin treatment. A detailed biochemical characterization and lipidomic profile was performed. Metformin reduces BMI, HOMA-IR, fSH and androstenedi…

Endocrine reproductive disordersmedicine.medical_specialtyendocrine system diseasesmedicine.drug_classlcsh:Medicinemedicine.disease_causeArticleInternal medicinemedicineHumansAndrostenedionelcsh:ScienceSphingolipidsMultidisciplinarybusiness.industrylcsh:Rdigestive oral and skin physiologynutritional and metabolic diseasesLipid metabolismMetabolismAndrogenSphingolipidPolycystic ovaryMetforminMetforminOxidative StressEndocrinologyLipidomicslcsh:QFemalebusinessOxidation-ReductionOxidative stressmedicine.drugPolycystic Ovary SyndromeScientific reports
researchProduct